NCT00990808

The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)

A Multiple Dose Study to Investigate the Effect of MK0859 on Lipoprotein Metabolism When Added to Ongoing Statin Therapy in Dyslipidemic Patients

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.

Conditions

• Dyslipidemia

Interventions

Type	Name	Description
DRUG	anacetrapib	\[Intervention Name: MK0859\] MK0859 100 mg tablet once daily for 8 weeks.
DRUG	Comparator: atorvastatin	Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
DRUG	Comparator: placebo to MK0859	Placebo to MK0859 once daily for 4 weeks.
DRUG	Comparator: placebo to atorvastatin	Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.

Timeline

• Start date: 2009-11-01
• Primary completion: 2011-06-01
• Completion: 2011-07-01
• First posted: 2009-10-07
• Last updated: 2015-06-04